Aeterna Zentaris Inc. (AEZS): Price and Financial Metrics
AEZS Price/Volume Stats
Current price | $2.19 | 52-week high | $3.38 |
Prev. close | $2.08 | 52-week low | $1.36 |
Day low | $2.01 | Volume | 49,600 |
Day high | $2.19 | Avg. volume | 17,157 |
50-day MA | $1.91 | Dividend yield | N/A |
200-day MA | $2.22 | Market Cap | 10.63M |
AEZS Stock Price Chart Interactive Chart >
Aeterna Zentaris Inc. (AEZS) Company Bio
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company was founded in 1991 and is based in Summerville, South Carolina.
Latest AEZS News From Around the Web
Below are the latest news stories about AETERNA ZENTARIS INC that investors may wish to consider to help them evaluate AEZS as an investment opportunity.
Aeterna Zentaris Reports Third Quarter 2023 Financial Results- Launch of Ghryvelin™ in a number of key countries in the European Economic Area - Approval of Macrilen® in South Korea in September - Ended the quarter with $38.8 million in cash, expected to fund operations and advancement of priority pipeline programs into 2025 TORONTO, ONTARIO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmac |
Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference– Live moderated webcast with Klaus Paulini, Chief Executive Officer of Aeterna Zentaris on Wednesday, October 25th at 10:00 AM ET TORONTO, ONTARIO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris will participate a |
Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceTORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY in person and virtually. Dr. P |
Aeterna Zentaris (AEZS) Reports Q2 Loss, Tops Revenue EstimatesAeterna Zentaris (AEZS) delivered earnings and revenue surprises of 40.23% and 104.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Aeterna Zentaris Reports Second Quarter 2023 Financial ResultsEnded the quarter with $42.2 million in cash, expected to fund operations into 2025Driving patient recruitment for Phase 3 DETECT trial for the diagnosis of Childhood Onset Growth Hormone Deficiency TORONTO, ONTARIO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and o |
AEZS Price Returns
1-mo | 17.11% |
3-mo | 17.74% |
6-mo | -12.40% |
1-year | -18.28% |
3-year | -92.25% |
5-year | -98.12% |
YTD | 17.74% |
2023 | -41.51% |
2022 | -64.20% |
2021 | -16.50% |
2020 | -53.24% |
2019 | -69.05% |
Continue Researching AEZS
Want to see what other sources are saying about Aeterna Zentaris Inc's financials and stock price? Try the links below:Aeterna Zentaris Inc (AEZS) Stock Price | Nasdaq
Aeterna Zentaris Inc (AEZS) Stock Quote, History and News - Yahoo Finance
Aeterna Zentaris Inc (AEZS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...